GlassScriptPhysician profile
Morgan Leeth
NPI 1720679640
$4,305.45
in general payments reported to CMS, 2019-2025
29 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $526 · 2022: $835 · 2023: $109 · 2024: $1,048 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.13 |
| Education | $117.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.98 | 2021-2025 | |
| Ardelyx, INC. | $389.04 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.91 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Qol Medical, LLC | $279.76 | 2021-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $277.25 | 2022-2025 | Stelara, Tremfya |
| Genzyme Corporation | $239.49 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $237.40 | 2021-2025 | Entyvio |
| Celgene Corporation | $179.65 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $164.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $163.94 | 2022-2025 | |
| Lilly USA, LLC | $144.53 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $136.96 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $135.28 | 2024-2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $135.28 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $108.77 | 2022-2025 | Dupixent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $100.53 | 2024 | Axonics |
| Redhill Biopharma INC. | $85.10 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $77.23 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $65.38 | 2022-2025 | |
| Novo Nordisk INC | $57.10 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $40.34 | 2021-2023 | |
| Evoke Pharma, INC. | $34.38 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $22.47 | 2024 | |
| Daiichi Sankyo INC. | $21.72 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.84 | 2022 | |
| Celltrion USA INC. | $17.03 | 2024 | Zymfentra |
| Dexcom, INC. | $16.06 | 2023 | Dexcom G6 Transmitter |
| Amgen INC. | $14.70 | 2021 | |
| Merck Sharp & Dohme LLC | $13.58 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Leeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.